Company
Vivid Dx
We are transforming the detection of sepsis-causing pathogens and AMR.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Customers
- providers
Claim, correct or request removal
Record updated 17 September 2026
About
At Vivid Dx, we’ve reimagined the process from the ground up — creating a next-generation diagnostics platform to detect a broad number of sepsis-causing pathogens in 30 minutes and delivers phenotypic antimicrobial susceptibility (AST) results in just 3 hours.
Funding snapshot
- Total raised
- $15MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Seed, $15M2026-07
Funding rounds
- Seed
- $15M2026-07, Company stated
- Grant
- 2025-05
- Round, 2024
- 2024-04
Products
- Hardware
- Vivid Dx rapid diagnostics platform
Loading relationship preview